var data={"title":"Technetium Tc-99m mebrofenin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m mebrofenin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/482690?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=technetium-tc-99m-mebrofenin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Technetium Tc-99m mebrofenin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207110\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Choletec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207112\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207121\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hepatobiliary imaging:</b> IV (based on 70 kg patient): 2 to 5 mCi (74 to 185 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801884\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207122\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Serum bilirubin &gt;1.5 mg/dL: 3 to 10 mCi (111 to 370 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452818\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Choletec:  [contains methylparaben, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452817\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207191\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV administration. Test should be performed while patient is fasting; avoid interference with opioids by delaying the study for 4 hours after the last dose. Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207118\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Imaging agent:</b> Hepatobiliary imaging agent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13255276\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207123\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Dermatologic: Skin rash, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49497625\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to technetium Tc 99m mebrofenin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207158\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Potential of allergic reactions in patients receiving multiple doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meperidine or morphine sulfate use: Recent use may delay intestinal transit of imaging agent resulting in nonvisualization of intestinal activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Delayed visualization or nonvisualization of the gallbladder may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patient should be fasting (at least 4 hours) prior to administration to prevent a false positive result (nonvisualization of gallbladder).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207178\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207179\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein, 1999).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein, 1999; ICRP, 2000; Parker, 2004). Pregnancy status should be determined in women of childbearing potential (Parker, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13207181\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Technetium Tc 99m is excreted into breast milk. The manufacturer recommends substituting formula for breast-feeding. Information specific to technetium Tc 99m mebrofenin has not been located; however, one source recommends stopping breast-feeding following administration of technetium Tc 99m compounds for 12 hours after administration (ICRP, 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following the administration of a radiopharmaceutical, women with a well-established milk supply should pump at normal feeding times and discard the milk until breast-feeding may be resumed (Harding, 1995; Mountford, 1989). Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breast-feeding cannot be made (Mountford, 1989; Rubow, 1994). Elective diagnostic procedures should be delayed until breast-feeding has stopped (Parker, 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (USNRC, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49497627\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49497628\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Detectable in hepatic duct and gallbladder within 10 to 15 minutes and in intestinal tract within 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 6.02 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (1% within 3 hours; 3% within 3 hours in patients with elevated serum bilirubin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777099\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bridatec (ES, FI, NL);</li>\n      <li>Cholecis (GB);</li>\n      <li>Cholediam (IE);</li>\n      <li>Hibida (CZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ, &quot;Administered Radionuclides in Pregnancy,&quot; <i>Teratology</i>, 1999, 59(4):236-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-mebrofenin-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balon HR, Brill DR, Fink-Bennett DM, et al, &quot;Society of Nuclear Medicine Procedure Guideline for Hepatobiliary Scintigraphy,&quot; 2001. Available at http://interactive.snm.org/docs/pg_ch11_0703.pdf. Last accessed August 30, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choletec (technetium Tc 99m mebrofenin) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al, &quot;Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers,&quot; <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP), &quot;Pregnancy and Medical Radiation,&quot; <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-mebrofenin-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,&quot; <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-mebrofenin-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al, &quot;The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry,&quot; <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-mebrofenin-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stabin MG and Breitz HB, &quot;Breast Milk Excretion of Radiopharmaceuticals: Mechanisms, Findings, and Radiation Dosimetry,&quot; <i>J Nucl Med</i>, 2000, 41(5):863-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-mebrofenin-drug-information/abstract-text/10809203/pubmed\" target=\"_blank\" id=\"10809203\">10809203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16814 Version 43.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13207110\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13207112\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13207121\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22801884\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13207122\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20452818\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452817\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13207191\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13207118\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13255276\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13207123\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49497625\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13207158\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13207178\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13207179\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13207181\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49497627\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F49497628\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777099\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16814|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=technetium-tc-99m-mebrofenin-patient-drug-information\" class=\"drug drug_patient\">Technetium Tc-99m mebrofenin: Patient drug information</a></li></ul></div></div>","javascript":null}